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Abstract
Background: Buruli ulcer (BU) is a progressive disease of subcutaneous tissues caused by Mycobacterium ulcerans. The pathology
of BU lesions is associated with the local production of a diffusible substance, mycolactone, with cytocidal and
immunosuppressive properties. The defective inflammatory responses in BU lesions reflect these biological properties of the
toxin. However, whether mycolactone diffuses from infected tissues and suppresses IFN-c responses in BU patients remains
unclear.
Methodology/Principal Findings: Here we have investigated the pharmacodistribution of mycolactone following injection
in animal models by tracing a radiolabeled form of the toxin, and by directly quantifying mycolactone in lipid extracts from
internal organs and cell subpopulations. We show that subcutaneously delivered mycolactone diffused into mouse
peripheral blood and accumulated in internal organs with a particular tropism for the spleen. When mice were infected
subcutaneously with M. ulcerans, this led to a comparable pattern of distribution of mycolactone. No evidence that
mycolactone circulated in blood serum during infection could be demonstrated. However, structurally intact toxin was
identified in the mononuclear cells of blood, lymph nodes and spleen several weeks before ulcerative lesions appear.
Importantly, diffusion of mycolactone into the blood of M. ulcerans–infected mice coincided with alterations in the functions
of circulating lymphocytes.
Conclusion: In addition to providing the first evidence that mycolactone diffuses beyond the site of M. ulcerans infection,
our results support the hypothesis that the toxin exerts immunosuppressive effects at the systemic level. Furthermore, they
suggest that assays based on mycolactone detection in circulating blood cells may be considered for diagnostic tests of
early disease.
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Introduction
Buruli ulcer (BU) is a cutaneous disease caused by Mycobacterium
ulcerans,leading totheformationofprogressiveulcers,withextensive
skin and soft tissue destruction. The presence of a coagulative
necrosis forming a nidus for colonies of bacilli, accompanied by
minimal inflammation, are considered the most reliable features for
the histopathological diagnosis of BU disease [1]. These hallmarks
of BU lesions in fact reflect the dual properties of a macrolide toxin
produced by M. ulcerans, mycolactone, which plays a critical role in
bacterial virulence [2,3]. This unique polyketide has been shown to
be a potent cytocidal molecule in vitro and in vivo [4,5,6,7]. In
addition, mycolactone displays significant immunosuppressive
properties at non-cytotoxic doses towards a wide range of immune
cells [5,8,9,10].
Numerous studies have reported defective IFN-c responses in
BU patients, using assays of PBMC restimulation ex-vivo
[11,12,13,14,15,16]. IFN-c responses to M. ulcerans antigens are
reduced in BU patients compared to healthy controls
[11,12,13,14], particularly during the early stage of the disease
[15,16]. M. ulcerans infection-associated reduction of IFN-c
responses was initially thought to be restricted to mycobacterial
antigens. In fact, systemic suppression of IFN-c responses is not
antigen-specific, and resolves after surgical excision of the lesion
[17]. Notably, the optimal growth temperature of M. ulcerans is
below 35uC [18], and animal studies suggest that the bacilli remain
essentially localized within ulcerative lesions in subcutaneous
tissues [5]. The fact that immunosuppression in BU patients
resolves after removal of infected tissues therefore strongly suggests
that bacterial factors, such as mycolactone, may diffuse from the
bacilli colonies and exert immunosuppressive effects at the
systemic level [19].
In the present study, we have investigated the pharmacodis-
tribution of mycolactone following injection in animal models by
tracing a radiolabeled form of the toxin in vivo, and by directly
assessing the integrity and the quantity of mycolactone in lipid
www.plosntds.org 1 October 2008 | Volume 2 | Issue 10 | e325extracts from internal organs and cell subpopulations. Our
observation that mycolactone diffuses in blood and spleen, and
concentrates within distinct immune cellular subsets, supports the
notion that mycolactone permits M. ulcerans to establish long-term




Six week old BalB/cByJIco and C57BL/6JIco female mice were
purchased from Charles Rivers Laboratories. Mice were housed in
a BSL-3 animal facility at the Institut Pasteur, in full compliance
with French and European regulation and guidelines on
experiments with live animal.
Mycolactone preparation
Mu 1615 wt (ATCC 35840) was obtained from the Trudeau
collection. This strain produces a mixture of mycolactones A/B
and C [20]. Bacteria were cultivated in Dubos medium
complemented with oleic acid-albumin-dextrose 10% (OADC,
Becton Dickinson) in spinner flasks at 32uC. To generate
14C-
labeled mycolactone, exponentially growing cultures were supple-
mented weekly with 15 ml [1-
14C] propionic acid (MP, 40–
60 mCi/mmol) and 15 ml [1,2-
14C] acetic acid (MP, 50–
120 mCi/mmol). After three weeks, mycolactone was purified
from bacterial pellets as previously described [2]. The resulting
14C-radiolabeled mycolactone showed an activity of 300 cpm/mg.
Its biological activity, as measured by the assay described below,
was equivalent to that of the unlabeled molecule (data not shown).
Distribution of radiolabeled mycolactone in blood and
organs
BALB/C mice were injected with 300 mg radiolabeled myco-
lactone via either the sc, ip or iv routes. Animals were bled at the
indicated time points, and serum radioactivity monitored by liquid
scintillation counting. 24 h post injection, animals were sacrificed
and spleen, kidney, liver, brain, fat tissues and intestine were
harvested and ground with a Potter-Elvehjem homogeniser in a
minimal volume of H2O. The radioactivity of the resulting
suspensions was measured by liquid scintillation counting.
Density gradient fractionation
Peripheral blood mononuclear cells (PBMCs) were isolated from
whole blood by density gradient centrifugation using Lympholyte-
Mammal (Cedarlane, Ontario, Canada) following the instructions
of the manufacturer. For PBMC purification from lymph nodes
and spleens, organs were first homogenized and passed through
nylon filters with 100 mm-diameter pores (Cell Strainer, BD
Falcon
TM), then submitted to density gradient centrifugation using
Lympholyte-M (Cedarlane, Ontario, Canada).
Quantitative analysis of mycolactone presence in mouse
organs and cell subsets
Total lipids were extracted from homogenized organs or cell
suspensions with chloroform-methanol (2:1, vol/vol) for 2 h at
room temperature. After separation from the aqueous phase, the
organic phase was dried and the resulting material resuspended in
ice-cold acetone. This acetone-soluble fraction was resuspended in
methanol for analysis by ESI-LC-MS and ESI-LC-MS/MS
(Helium collision gas), using a Finnigan LCQ ion trap (Thermo
Finnigan, USA) coupled with a HP1100 LC fitted with
ThermoHypersil BDS C8 column (5 mm, 4.66250 mm). Myco-
lactones were eluted with a 40-min gradient from 55 to 95%
acetonitrile in water. The presence of m/z 765.5 (mycolactone A/
B) and m/z 749.5 (mycolactone C) was determined by comparison
of the MS/MS spectra with those from pure mycolactone
preparations. As elution peak areas were directly proportional to
mycolactone concentration, 5 ml of a 1 mg/ml reference solution
of mycolactone A/B was analyzed with each set of biological
samples and used as a standard. The elution peak areas of
mycolactones A/B and C were combined to evaluate the total
mycolactone concentration in each sample.
Assay of biological activity
The human T cell line Jurkat subclone E6.1 was cultured in
RPMI with 10% FCS, 2 mM L-glutamine, 100 IU/ml penicillin
and 100 mg/ml streptomycin. Cells were incubated in microtiter
plates (10
5 cells/well) with serum aliquots (2,5 ml) for 6 h in the
presence or absence of 400 ng/ml mycolactone A/B, then
activated with 25 ng/ml PMA and 500 ng/ml ionomycin (both
from Calbiochem, La Jolla, CA) for 16 h. Culture supernatants
were assayed for interleukin (IL)-2 by ELISA (R&D, Minneapolis,
MN). For whole blood stimulation assays, 200 ml of pooled blood
samples (n=6) were incubated with anti-CD3 and -CD28
antibodies (both at 10 mg/ml) for 24 h and the production of
IL-2 measured by ELISA (R&D, Minneapolis, MN).
Results
Pharmacokinetics of mycolactone in vivo
To investigate the biodistribution of mycolactone, a radiola-
beled molecule was generated by feeding M. ulcerans cultures with
[1-
14C] propionic acid and [1,2-
14C] acetic acid. Purified
14C-
labeled mycolactone was injected into mice using three alternative
routes of administration, namely subcutaneous (sc), intraperitoneal
(ip), or intravenous (iv), and the radioactivity levels in circulating
blood were then monitored during 24 hours, after which animals
were euthanised (Figure 1A). We found that the blood concentra-
tion of iv-delivered mycolactone declined progressively, likely
Author Summary
Mycolactone is a lipophilic molecule produced by Myco-
bacterium ulcerans, the causative agent of the skin disease
Buruli ulcer (BU). Mycolactone displays unique cytocidal
and immunosuppressive properties that are reflected
locally by massive tissue necrosis and minimal inflamma-
tion. Here we investigated whether mycolactone diffuses
from infected tissues and exerts immunosuppressive
properties at the systemic level. We used both a
radiolabeled form of the toxin and a direct LC-MS/MS
analysis of lipid extracts from internal organs and cell
subpopulations to investigate the pharmacodistribution of
mycolactone in vivo. Using a mouse model of subcutane-
ous infection with M. ulcerans, we show that mycolactone
distributes far beyond the sphere of its cytocidal action.
The toxin diffused from infected tissues into the blood and
the spleen, where it concentrated in mononuclear cell
subsets. Importantly, mycolactone was detected in circu-
lating blood several weeks before ulcerative lesions
develop. The presence of mycolactone in blood cells was
associated with a decreased capacity of circulating
lymphocytes to produce interleukin-2 upon stimulation.
In addition to providing the first evidence that mycolac-
tone targets key immune cell populations in infected
hosts, this work suggests that mycolactone detection in
peripheral blood cells may form the basis of diagnostic
tests of early disease.
In Vivo Distribution of Mycolactone
www.plosntds.org 2 October 2008 | Volume 2 | Issue 10 | e325Figure 1. Pharmacokinetics of mycolactone in vivo. Panel A shows the kinetics of mycolactone concentration in the circulating blood of mice
following an intravenous (IV), intraperitoneal (IP) or subcutaneous (SC) injection of 300 mgo f
14C-labeled mycolactone. Panel B shows radioactivity
levels in various internal organs 24 h post injection of mycolactone via these three administration routes. The left axis indicates cpm levels and the
right one the corresponding mycolactone concentrations, for a 300 cpm/mg activity. Data were acquired on pools of blood samples or homogenized
organs (n=3). Panel C illustrates the preferential distribution of mycolactone in the spleen, versus kidney and liver, following injection via the IV
(n=5) or the SC (n=5) route in three independent experiments. Radioactivity levels in each organ were compared with the Friedman Test
(Nonparametric Repeated Measures ANOVA) and Dunn’s multiple comparison post-test (*: p,0,05; **: p,0,01).
doi:10.1371/journal.pntd.0000325.g001
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the blood concentration of mycolactone increased slowly following
sc or ip delivery. No circulating mycolactone could be detected
after 24 hours, for any of the administration routes. The levels of
mycolactone in spleen, kidneys, liver, brain and fat tissues were
then investigated 24 hours post-injection, by measuring the
radioactivity of homogenized organs (Figure 1B). Mycolactone
was found in each of the organs except brain, irrespective of the
injection route. The relative distribution of mycolactone in spleen,
kidney and liver following iv or sc injection was examined.
Interestingly, the levels of radioactivity found in the spleen were
significantly higher than those of liver and kidney, suggesting that
mycolactone displays a relative tropism for this organ (Figure 1C).
Mycolactone distributes to internal organs without
evidence of structural alteration
To determine whether mycolactone is present in internal organs
as an intact molecule, or as degradation products, we repeated the
experiment with equivalent doses of unlabeled mycolactone. Here
total lipids were extracted from the various organs and their
acetone-soluble fractions were analyzed by LC-MS/MS. In each
lipid extract, the typical ion trace of intact mycolactone A/B (m/z
765) and C (m/z 749) was observed (Figure 2). No evidence that
mycolactone had been metabolized by (for example) hydroxyl-
ation, methylation, demethylation, double hydroxylation or loss of
the side-chain was observed. Furthermore, a quantitative analysis
of mycolactone by LC-MS/MS confirmed the relative tropism of
mycolactone for the spleen, suggesting that mycolactone may
preferentially target this lymphoid compartment (data not shown).
Mycolactone targets mononuclear cells in blood and
spleen cell suspensions
The question of mycolactone’s tropism was investigated by
incubating mycolactone with either blood cells or splenocytes and
subjecting the cell suspension to density gradient fractionation.
This method allows the purification of mononuclear cells
(lymphocytes, monocytes, DCs and macrophages) from extracel-
lular medium, red cells and granulocytes. Strikingly, within
4 hours of incubation with whole heparinized blood, mycolactone
(total A/B and C forms) distributed primarily in the mononuclear
cell compartment, with only a marginal presence in the
extracellular medium and in the red cell/granulocyte fraction
(Figure 3). A similar distribution profile was observed when
mycolactone was incubated with spleen cell suspensions for
1 hour, strongly suggesting that mycolactone has a particular
affinity for mononuclear cell subsets.
M. ulcerans–produced mycolactone diffuses into internal
organs of experimentally infected mice
To evaluate the physiological relevance of this finding, C57BL/
6 mice were infected experimentally with M. ulcerans, by injection
of live bacilli into the tail via the sc route. We have shown
previously that this mode of inoculation results in a progressive
infection, with multiplication of the bacilli and development of skin
ulcerations within 10 weeks following injection of 10
4 bacilli [21].
Importantly, although bacilli can disseminate to the draining
lymph nodes in this model, they do not reach the spleen [5]. As
ulcerative lesions developed, mice were sacrificed and the presence
of mycolactone was assessed in spleen, brain, liver, kidney and
Figure 2. Structural integrity of mycolactone following diffusion into internal organs. The ion trace for m/z 765 (Mycolactone A/B) and m/
z 749 (Mycolactone C), and the corresponding MS/MS spectra are shown for the spleen lipid extract of a mouse injected with mycolactone via the sc
route. Data are representative of two independent experiments.
doi:10.1371/journal.pntd.0000325.g002
In Vivo Distribution of Mycolactone
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extracts. In accordance with our previous findings with myco-
lactone-injected mice, mycolactone was detected in spleen,
kidneys, and liver but not in the brain (Figure 4). Importantly,
mycolactone was structurally intact in these internal organs (data
not shown).
Presence of mycolactone in serum during M. ulcerans
infection
We investigated the presence of mycolactone in the sera of
infected mice indirectly, by taking advantage of its immunosup-
pressive activity on activation-induced IL-2 production by human
lymphocytes [22] (Figure 5A). Here C57BL/6 mice were infected
by footpad injection of either the wild-type strain (wtMu), or a
mycolactone-deficient strain of M. ulcerans (mup045Mu). Sera
harvested at different pre-ulcerative stages of the disease were
incubated with Jurkat T lymphocytes prior to cell stimulation.
Control mouse sera caused a basal inhibition of activation-induced
IL-2 production by T cells that was efficiently removed by a heat
Figure 3. Mycolactone targets mononuclear cells in blood and
spleen cell suspensions. The distribution of mycolactone in the
gradient density fractions of whole blood or spleen cell suspensions is
shown. Mycolactone was added to whole blood (20 mg/ml) or spleen
cell suspensions (20 mg/spleen) and incubated for 4 h or 1 h,
respectively. The amount of mycolactone distributing in each gradient
fractions was then determined by ESI-LC-MS quantitative analysis of
their acetone-soluble lipid extracts. Data are mean percentages and SD
of duplicate measurements, and are representative of two independent
experiments.
doi:10.1371/journal.pntd.0000325.g003
Figure 4. M. ulcerans–produced mycolactone diffuses in internal
organs of experimentally infected mice. The distribution of
mycolactone is shown in internal organs of mice ten weeks post sc
infection with 10
4 M. ulcerans bacilli. The amount of mycolactone was
determined by ESI-LC-MS analysis of acetone-soluble lipid extracts
prepared from pools of 5 homogenized organs. Data correspond to the
calculated amount of total mycolactones (A/B and C forms) per organ,
nd: not detected.
doi:10.1371/journal.pntd.0000325.g004
Figure 5. Presence of mycolactone in serum during M. ulcerans
infection. A) The dose-dependent immunosuppressive activity of
mycolactone on the IL-2 production of Jurkat T cells is shown. IL-2
concentration was measured in culture supernatants of Jurkat T cells
incubated with mycolactone A/B for 6 h prior to stimulation with PMA/
ionomycin for 16 h. B) The effect of control mouse sera on stimulation-
induced production of IL-2 by Jurkat T cells is shown, by comparison to
cells incubated in the absence of serum. The graph shows that this
inhibitory effect can be neutralized by heating the control mouse sera
at 90uC for 10 min (HT), prior to addition onto Jurkat T cells. Controls
include cells in the absence of stimulation (NS), and cells activated in
the presence of sera spiked with mycolactone (400 ng/ml), then heat-
treated. C) Immunosuppressive activity of sera harvested from mice
infected with wild-type M. ulcerans (wtMu) or the mycolactone deficient
mutant mup045Mu, as compared to sera from uninfected animals. Data
are mean and SD of duplicate measurements of IL-2 production by
Jurkat T cells activated in the presence of mouse sera (n=4), and are
representative of two independent experiments.
doi:10.1371/journal.pntd.0000325.g005
In Vivo Distribution of Mycolactone
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properties, heat-treated sera from wtMu-infected mice did not
differ from those of controls (Figure 5C). Furthermore, no
evidence that mycolactone distributes in the sera of wtMu-infected
mice could be demonstrated by LC-MS/MS analysis of ethyl
acetate extracts, at any stage of the disease (data not shown).
Mycolactone gains access to mononuclear cell
populations during M. ulcerans infection
Having shown that mycolactone has a particular affinity for
mononuclear cells in vitro, we assayed for its presence in this
particular cellular subset in vivo. Blood samples, lymph nodes and
spleens were collected from mice infected with wtMu, or
mup045Mu as controls, and cell suspensions submitted to gradient
density fractionation. Total lipids were then extracted from
mononuclear cell pellets and their acetone-soluble fractions
analyzed by LC-MS/MS. In parallel, the functional properties
of peripheral blood lymphocytes (PBLs) were evaluated by a whole
blood stimulation assay. After 6 weeks of infection with wtMu, that
is 4 weeks before ulcerative lesions develop (Figure 6A), myco-
lactone was detected in PBMCs and in mononuclear cells of the
lymph nodes (both draining and distant) and the spleen (Figure 6B).
Diffusion of mycolactone into the blood of wtMu-infected mice did
not alter the number or the viability of CD4
+ and CD8
+ blood T
cells (data not shown). However, it correlated with a decreased
capacity of PBLs to produce IL-2 in response to stimulation. In
contrast, systemic IL-2 responses of mice infected with mup045
Mu were stable and comparable to those of uninfected controls
(Figure 6C).
Discussion
BU is a tropical disease receiving far less attention than TB and
leprosy, although it is more common in some endemic regions of
West Africa. In contrast to these other two mycobacterioses, BU is
acquired from the environment following inoculation of M. ulcerans
in the dermis by a mechanism involving aquatic niches and insect
vectors although the exact mode of transmission remains unknown
[3]. BU starts as a painless subcutaneous nodule, oedema or
plaque, enlarging over time. As lesions progress, ulcers eventually
form that are characterized by an extensive necrosis of
subcutaneous tissues accompanied by minimal inflammation
[1,23]. The pathology of the disease is closely associated with
the production of a lipophilic toxin, mycolactone. This macrocy-
clic polyketide is highly cytotoxic to a variety of mammalian cells in
vitro, and the injection of mycolactone into the skin of guinea pigs is
sufficient to provoke ulcers [2]. Although the presence of
mycolactone is reflected locally by its damaging effects on infected
tissues any investigation of its diffusion outside the ulcerative lesion
has been rendered difficult by the lack of a detection tool for this
poorly immunogenic compound. In the present study, we have
Figure 6. Mycolactone is present in the mononuclear cells of M. ulcerans-infected animals. C57BL/6 mice (n=3) were infected by footpad
injection of 10
4 wtMu or mup045Mu bacilli. The distribution of mycolactone in PBMCs and in the mononuclear cell fraction of draining lymph nodes
(DLNs), inguinal lymph nodes (ILNs) and spleens (Spleen) is shown 6 weeks post infection. Mononuclear cells were isolated from pooled samples of
whole blood (1 ml), pooled DLNs (n=3), or from the ILNs and spleens of 3 individual mice. Acetone-soluble lipid were then extracted from cell pellets
and mycolactone concentrations determined by quantitative LC/MS-MS analysis. Means and SD are shown for ILNs and spleens. C) IL-2 production
after whole blood stimulation with anti-CD3 and -CD28 antibodies for 24 h. Data are mean and SD of IL-2 concentrations, as measured in duplicate
for pooled blood samples (n=4) after 2, 4 and 6 weeks of infection, and are representative of three independent experiments. Differences in IL-2
concentration between groups were analyzed by one-way ANOVA (*: p,0,05; **: p,0,01).
doi:10.1371/journal.pntd.0000325.g006
In Vivo Distribution of Mycolactone
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beyond the sphere of its cytocidal action at the site of inoculation,
or at the point of M. ulcerans infection.
Mycolactone is cytotoxic and pro-apoptotic at micromolar
concentrations, but in addition non-cytotoxic doses in the
nanomolar range can efficiently suppress the functional biology
of several types of mononuclear cells. Mycolactone was shown to
inhibit the activation-induced production of IL-2 by human
lymphocytes, and of TNF by monocytes and macrophages [5,9].
Mycolactone also blocked the capacity of dendritic cells (DCs) to
prime cellular responses and to produce chemotactic signals of
inflammation [8]. Lymphocytes, monocytes, DCs and macro-
phages compose the mononuclear cell fraction of blood and
lymphoid organs. Together, these cell populations contribute to
the generation of innate and acquired cellular immune responses,
which are critical for protective immunity against mycobacterial
infections. The fact that mycolactone targets mononuclear cells in
mice infected with M. ulcerans strongly suggests that these cell
subsets are immunosuppressed by the toxin in vivo.
The organ distribution of mycolactone revealed a relative
tropism of this molecule for the spleen, which is similar to that of
other lipophilic immunosuppressive compounds such as rapamy-
cin or FK506 [24,25]. However these two drugs are metabolized
in the liver, which produces a large array of metabolites [26,27].
Surprisingly, mycolactone was preserved in all the organs
(including the liver) that we analyzed by LC-MS/MS, and no
metabolite could be identified. Further studies, for example the
evaluation of toxin levels in bile, faeces and urine, will be required
to determine how infected animals eliminate mycolactone.
In contrast to FK506 and rapamycin, which concentrate
primarily in erythrocytes (.90%) and only minimally in
lymphocytes (,1%) in circulating blood, we found that myco-
lactone concentrates in mononuclear cells [24,28]. This is true
both for whole blood and for splenocyte cell suspensions, which
are richer in lymphocytes. FK506 and rapamycin are structural
analogues binding the same intracellular receptor FKBP12,
although the resulting complex targets a different molecule. Their
sequestration by red blood cells is explained by the high
immunophilin levels of erythrocytes. For mycolactone the
molecular target and pathway of action of the toxin are still
unknown. Our findings, combined with the observation that
mycolactone is a potent immunosuppressor of monocytes,
macrophages, DCs and lymphocytes suggest that the molecular
target of mycolactone may be expressed preferentially by
mononuclear cells.
We detected structurally intact mycolactone in PBMCs 6 weeks
post infection with M. ulcerans, that is 4 weeks before ulcerative
lesions start to develop in this mouse model. This is the first
evidence that mycolactone diffuses outside the lesions of an
organism infected with M. ulcerans and circulates via peripheral
blood. BU is often diagnosed on the basis of clinical findings,
because laboratory diagnoses based on smear examination, M.
ulcerans cultures, or PCR detection require significant logistics and
equipment. Simple and rapid diagnostic field tests for BU are
urgently needed for this disease to be treated locally and
inexpensively. Our results obtained in the mouse model suggest
that assays based on mycolactone detection in circulating blood
cells may be considered for diagnostic tests of early disease. We are
currently trying to define ways to detect mycolactone directly in
the blood cells of BU patients, which may be applicable to
diagnosis in field conditions.
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